Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Labs

This article was originally published in The Tan Sheet

Executive Summary

Ross Products' "more normalized mid-single digit sales growth" for pediatric nutritionals business expected by mid-year or in second half of 2002 following division's 2.6% growth in 2001, Abbott Labs Division VP-Investor Relations John Thomas tells analysts Jan. 16. Ross revenue for year reached $2.08 bil.; Q4 sales were down 1.6% to $485 mil., with Thomas citing negative impact of "heavy competitive spending." Abbott is eyeing increased promotional activity, Q1 launch of Similac with Iron containing DHA/ARA fatty acids to boost pediatric nutritional sales (1"The Tan Sheet" Jan. 14, 2002, p. 3). Consolidated sales for Q4 and year were $4.45 bil (up 20%) and $16.29 bil. (up 18.5%), respectively. Earnings, including one-time charges, were $613.5 mil. for quarter, down 18.6%, and $1.55 bil. for year, a 44.4% drop...
Advertisement

Related Content

Mead DHA/ARA-Fortified Infant Formula Slated For February Release
Mead DHA/ARA-Fortified Infant Formula Slated For February Release

Topics

Advertisement
UsernamePublicRestriction

Register

PS093507

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel